Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

AstraZeneca places US$85mln bet on autoimmune cell therapy with Quell deal

Published 09/06/2023, 08:57
Updated 09/06/2023, 08:41
© Reuters.  AstraZeneca places US$85mln bet on autoimmune cell therapy with Quell deal

Proactive Investors - AstraZeneca PLC (LON:AZN) is placing an US$85mln bet on the autoimmune cell therapy sector with Quell Therapeutics - its latest licensing partner.

As well as a promising single treatment 'cure' for Type-1 diabetes, Quell is also working on drugs for inflammatory bowel disease.

Its scientists are working on a technology that employs engineered regulatory T (Treg) cell therapies to curtail immune attacks, an approach shared by GentiBio, Kyverna Therapeutics and Sonoma Biotherapeutics.

AstraZeneca's investment paves the way for further exploration of this technology's versatility.

On top of the initial US$85mln, Quell may receive over US$2bn if specific milestones are reached.

The company has already raised approximately US$220mln.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.